HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Acute Myeloid Leukemia (Acute Myelogenous Leukemia)

Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES.
Also Known As:
Acute Myelogenous Leukemia; Acute Myeloblastic Leukemia; Myelogenous Leukemia, Acute; Acute Myelocytic Leukemia; Acute Nonlymphocytic Leukemia; Leukemia, Myeloid, Acute; ANLL; Acute Myeloid Leukemia with Maturation; Acute Myeloid Leukemia without Maturation; Leukemia, Myeloblastic, Acute; Leukemia, Myelocytic, Acute; Leukemia, Myeloid, Acute, M1; Leukemia, Myeloid, Acute, M2; Leukemia, Nonlymphoblastic, Acute; Myeloblastic Leukemia, Acute; Myelocytic Leukemia, Acute; Myeloid Leukemia, Acute, M1; Myeloid Leukemia, Acute, M2; Nonlymphoblastic Leukemia, Acute; Acute Myeloblastic Leukemias; Acute Myelocytic Leukemias; Acute Myelogenous Leukemias; Acute Myeloid Leukemias; Acute Nonlymphoblastic Leukemia; Acute Nonlymphoblastic Leukemias; Acute Nonlymphocytic Leukemias; Leukemia, Acute Myeloblastic; Leukemia, Acute Myelocytic; Leukemia, Acute Myelogenous; Leukemia, Acute Myeloid; Leukemia, Acute Nonlymphoblastic; Leukemia, Acute Nonlymphocytic; Leukemias, Acute Myeloblastic; Leukemias, Acute Myelocytic; Leukemias, Acute Myelogenous; Leukemias, Acute Myeloid; Leukemias, Acute Nonlymphoblastic; Leukemias, Acute Nonlymphocytic; Myeloblastic Leukemias, Acute; Myelocytic Leukemias, Acute; Myelogenous Leukemias, Acute; Myeloid Leukemias, Acute; Nonlymphoblastic Leukemias, Acute; Nonlymphocytic Leukemias, Acute; Leukemia, Myelogenous, Acute; Leukemia, Nonlymphocytic, Acute; Myeloid Leukemia, Acute; Nonlymphocytic Leukemia, Acute
Networked: 14185 relevant articles (1624 outcomes, 1882 trials/studies)

Relationship Network

Disease Context: Research Results

Related Diseases

1. Leukemia
2. Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
3. Myelodysplastic Syndromes (Myelodysplastic Syndrome)
4. Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
5. BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)

Experts

1. Kantarjian, Hagop: 114 articles (09/2015 - 01/2002)
2. Marcucci, Guido: 92 articles (11/2015 - 09/2003)
3. Ravandi, Farhad: 88 articles (11/2015 - 02/2004)
4. Cortes, Jorge: 82 articles (09/2015 - 08/2002)
5. Garcia-Manero, Guillermo: 77 articles (12/2015 - 01/2002)
6. Faderl, Stefan: 76 articles (07/2015 - 08/2002)
7. Andreeff, Michael: 71 articles (07/2015 - 01/2002)
8. Appelbaum, Frederick R: 64 articles (08/2015 - 01/2002)
9. Berdel, Wolfgang E: 59 articles (09/2015 - 02/2002)
10. Bloomfield, Clara D: 59 articles (04/2014 - 08/2002)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Acute Myeloid Leukemia:
1. Cytarabine (Cytosar-U)FDA LinkGeneric
2. Daunorubicin (Cerubidine)FDA LinkGeneric
3. Cyclophosphamide (Cytoxan)FDA LinkGeneric
4. Etoposide (VP 16)FDA LinkGeneric
5. Granulocyte Colony-Stimulating Factor (G-CSF)IBA
6. fludarabineIBA
7. Mitoxantrone (Novantrone)FDA LinkGeneric
8. Interleukin-2 (IL2)IBA
9. Busulfan (Busulfex)FDA Link
10. gemtuzumab (gemtuzumab ozogamicin)FDA Link

Therapies and Procedures

1. Drug Therapy (Chemotherapy)
2. Bone Marrow Transplantation (Transplantation, Bone Marrow)
3. Transplants (Transplant)
08/20/2009 - "In acute myelocytic leukemia (AML), for patients who receive transplants during first complete remission (CR1), no prospective randomized study has compared relapse incidence (RI) to cell source. "
05/01/2015 - "This retrospective study considered the outcomes of 181 patients with acute myeloid leukemia (AML) transplanted in second complete remission (CR2) between January 2005 and April 2012 and who received either a myeloablative autologous stem cell transplant (Auto-SCT; n = 82; median age: 48 years; median follow-up: 45 months) or an umbilical cord blood (UCB) allogeneic SCT (n = 99, median age: 46 years; median follow-up: 36 months; conditioning regimens: myeloablative n = 21, reduced n = 78; single unit n = 37, double units n = 62). "
01/15/2015 - "Patients with acute myeloid leukemia (AML) in first relapse after initial Complete Remission (CR) lasting ≥1 month were stratified per the European Prognostic Index (EPI) into favorable, intermediate, and poor-risk groups based on duration of first CR, cytogenetics, age, and transplant history. "
02/01/2014 - "We analyzed 604 adults with acute myeloid leukemia in first complete remission (CR1) reported to the Center for International Blood and Marrow Transplant Research who received a reduced-intensity or nonmyeloablative conditioning HCT from an HLA-identical sibling, HLA-matched unrelated donor, or umbilical cord blood donor from 2000 to 2010. "
04/01/2010 - "Acute myeloid leukemia: when to transplant in first complete remission."
4. Transplantation (Transplant Recipients)
5. Stem Cell Transplantation